Publications by authors named "David D Thompson"

Claim this Profile
V
Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale.
Michael P Whyte, Kenji P Fujita, Scott Moseley, David D Thompson, William H McAlister

J Bone Miner Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asfotase alfa therapy for children with hypophosphatasia.
Michael P Whyte, Katherine L Madson, Dawn Phillips, Amy L Reeves, William H McAlister, David D Thompson

JCI Insight· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.
Michael P Whyte, Cheryl Rockman-Greenberg, Keiichi Ozono, Richard Riese, Scott Moseley, David D Thompson

J Clin Endocrinol Metab· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis.
Richard Eastell, David M Reid, Slobodan Vukicevic, Kristine E Ensrud, Andrea Z LaCroix, John R Thompson, David D Thompson

Bone· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
Andrea Z LaCroix, Trevor Powles, C Kent Osborne, Kevin Wolter, John R Thompson, David D Thompson

J Natl Cancer Inst· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Kristine Ensrud, Andrea LaCroix, John R Thompson, David D Thompson, Richard Eastell

Circulation· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lasofoxifene in postmenopausal women with osteoporosis.
Steven R Cummings, Kristine Ensrud, Pierre D Delmas, Andrea Z LaCroix, Slobodan Vukicevic, John Thompson, David D Thompson

N Engl J Med· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation.
Kimberly O Cameron, Bruce A Lefker, Hua Z Ke, Mei Li, Michael P Zawistoski, David D Thompson

Bioorg Med Chem Lett· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shifting the curve: an argument against tiered networks.
David D Thompson

Conn Med· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Xiao-Ning Wang, Hollis A Simmons, Christopher T Salatto, Patricia G Cosgrove, David D Thompson

Menopause· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats.
Kimberly O Cameron, Bruce A Lefker, Margaret Y Chu-Moyer, David T Crawford, Paul DaSilva Jardine, David D Thompson

Bioorg Med Chem Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats.
Hua Zhu Ke, D Todd Crawford, Hong Qi, Hollis A Simmons, Thomas A Owen, David D Thompson

J Bone Miner Res· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Richard Chesworth, Matthew D Wessel, Lisa Heyden, F Michael Mangano, Michael Zawistoski, David D Thompson

Bioorg Med Chem Lett· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia.
Hua Zhu Ke, Hong Qi, D Todd Crawford, Hollis A Simmons, Gang Xu, David D Thompson

J Bone Miner Res· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists.
Richard Chesworth, Michael P Zawistoski, Bruce A Lefker, Kimberly O Cameron, Robert F Day, David D Thompson

Bioorg Med Chem Lett· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
Hua Zhu Ke, George L Foley, Hollis A Simmons, Victor Shen, David D Thompson

Endocrinology· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing.
Mei Li, Hua Zhu Ke, Hong Qi, David R Healy, Yan Li, David D Thompson

J Bone Miner Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption.
Hua Zhu Ke, Hong Qi, A Frederik Weidema, Qing Zhang, Nattapon Panupinthu, David D Thompson

Mol Endocrinol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin.
Philip A Carpino, Bruce A Lefker, Steven M Toler, Lydia C Pan, John R Hadcock, David D Thompson

Bioorg Med Chem· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and biological characterization of capromorelin analogues with extended half-lives.
Philip A Carpino, Bruce A Lefker, Steven M Toler, Lydia C Pan, John R Hadcock, David D Thompson

Bioorg Med Chem Lett· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis